Fernández-Fernández L, Tejero E, Tieso A
Department of Surgery, General Hospital of Insalud, Soria, Spain.
Eur J Surg Oncol. 1995 Aug;21(4):388-90. doi: 10.1016/s0748-7983(95)92516-3.
In order to evaluate the usefulness of CA 72-4 tumour-associated antigen assay in colorectal carcinoma, we have studied 70 patients with benign colorectal diseases and 127 patients with colorectal cancer at different stages. The results were compared with those obtained by CEA and CA 19-9. No significant differences were found in any of the stages according to Dukes' classification when comparing stages A, B and C. However, there were differences with CEA (P < 0.001), CA 19-9 (P < 0.001) and CA 72-4 (P < 0.001) when comparing stages A, B and C with stage D. In the ROC curve, at a specificity of 95%, the sensitivities of CEA, CA 19-9 and CA 72-4 were 46.4%, 20.5% and 40.1%, respectively. In conclusion, CA 72-4 showed better sensitivity and specificity scores than CA 19-9. CEA increased individual sensitivity from 46.4% to 59.8% when combined with CA 72-4, showing a decrease of merely 0.9% in specificity.
为了评估癌胚抗原72-4（CA 72-4）肿瘤相关抗原检测在结直肠癌中的应用价值，我们研究了70例患有良性结直肠疾病的患者以及127例处于不同分期的结直肠癌患者。将结果与癌胚抗原（CEA）和糖类抗原19-9（CA 19-9）检测结果进行比较。根据Dukes分期比较A、B和C期时，各期之间未发现显著差异。然而，将A、B和C期与D期进行比较时，CEA（P < 0.001）、CA 19-9（P < 0.001）和CA 72-4（P < 0.001）存在差异。在ROC曲线中，当特异性为95%时，CEA、CA 19-9和CA 72-4的灵敏度分别为46.4%、20.5%和40.1%。总之，CA 72-4的灵敏度和特异性评分优于CA 19-9。CEA与CA 72-4联合使用时，个体灵敏度从46.4%提高到59.8%，而特异性仅下降0.9%。
